Lancet Gastroenterology & Hepatology

Papers
(The H4-Index of Lancet Gastroenterology & Hepatology is 74. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
GORD: pain, PPIs, and preciseness2025
Viral hepatitis: time for action663
Nationwide practice change after early termination of a randomised trial of laparoscopic pancreatoduodenectomy659
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply475
Lucky: Learning to Live Again475
EASL Congress 2024455
Treatment withdrawal in Crohn's disease: slowly becoming clearer409
Research in Brief381
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship306
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11295
Thanks to our peer reviewers and contributors280
Correction to Lancet Gastroenterol Hepatol 2025; 10: 418–30280
Appendicectomy: a disease-modifying treatment for ulcerative colitis?279
Voices from the frontline: how global funding cuts are reshaping the viral hepatitis response275
Developing policy for steatotic liver disease: an even better buy?273
Correction to Lancet Gastroenterol Hepatol 2026; 11: 314–22249
The central role of primary care in liver health245
Cyclic exclusive enteral nutrition in paediatric Crohn's disease231
The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus229
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium225
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial212
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial204
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t201
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement195
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension179
Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial175
Trends in alcohol-specific deaths in the UK and industry responses173
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study171
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial160
ACG 2024156
Long-term VEDOKIDS results: implications for practice and research153
Correction to Lancet Gastroenterol Hepatol 2022; 7: 627–47149
The pitfalls and promises of scoping reviews in gastroenterology literature – Authors’ reply144
Management of portal vein thrombosis in cirrhosis141
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere139
Water and sanitation for all135
Idiopathic gastroparesis consensus misses the patient's voice135
Research in Brief132
Uptick of food allergies in recent years—real or epiphenomenon?130
Has the time come for a systematic top-down approach in Crohn's disease?129
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply123
U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis122
Local and systemic therapy in liver cancer: the quest for synergy122
The potential of ctDNA in locoregional therapies for colorectal cancer114
All roads lead to the gut–brain microbiome network108
Bringing organ preservation closer for selected patients with rectal cancer104
Rare cause of dysphagia in a young woman103
Availability of point-of-care HBV tests in resource-limited settings101
Endoscopist deskilling: an unintended consequence of AI-assisted colonoscopy?100
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised p98
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial97
Sex and gender in inflammatory bowel disease outcomes and research96
Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study96
Resmetirom for NASH: balancing promise and prudence95
Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study95
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review93
Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial90
Lifting the minority tax in gastroenterology and hepatology86
The Year My Life Went Down the Toilet85
Management of malignant bowel obstruction – Authors' reply85
A women-focused matrix mentorship programme in gastroenterology84
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B83
Another arrow in the NASH quiver?82
Effects of lyophilised faecal filtrate compared with lyophilised donor stool on Clostridioides difficile recurrence: a multicentre, randomised, double-blinded, non-inferiority trial82
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment de81
Research in Brief80
Practicalities accessing precision medicine in biliary tract cancer80
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions79
18th Congress of the European Crohn's and Colitis Organisation79
An unusual complication after a variceal glue injection79
Britta Siegmund: answering the big questions in IBD78
The evolving clinical trial landscape in the MENA region74
Redefining palliation in malignant gastric outlet obstruction74
Managing inflammatory bowel disease: what to do when the best is unaffordable?74
Shitbag: the story of a diagnosis74
Robotic versus laparoscopic surgery for middle and low rectal cancer74
0.18006896972656